<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)

Table of step height. by Jianbo Jia (717814)

Subjects:

The well wall step. by Jianbo Jia (717814)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…The values represent the mean ± SEM, with significance set at p < 0.05 (*).…”

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

“…<p>Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes.…”

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Subjects: “…chronically infected patients…”

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Distribution of patients in the 4 age groups, mean value of IC-volume from both sides and separately for the left and right ICs. by Pingling Kwok (14896191)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. by Annaëlle Le Steunf (19838110)

“…<p>Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge.…”